CD19 and B-cell non-Hodgkin lymphoma: Regarding BiTEs, it is worth noting that blinatumomab, a dual-specific antibody targeting CD19 and CD3, has demonstrated enhanced efficacy in treating patients diagnosed with B cell lymphoma.